Last reviewed · How we verify

Human Amnion Allograft

University of North Dakota · FDA-approved active Biologic ✓ Verified May 2026 Quality 5/100

Human Amnion Allograft is a Biologic drug developed by University of North Dakota. It is currently FDA-approved. Also known as: AmnioExCel.

Human Amnion Allograft is a product used in clinical trials for various conditions, including Diabetic Foot Ulcer, Venous Leg Ulcer, Degenerative Disc Disease, Spondylolisthesis, and Spondylosis. It is classified as a SEQUESTERING AGENT, specifically a bilirubin sequestering agent, and is derived from protein.

At a glance

Generic nameHuman Amnion Allograft
Also known asAmnioExCel
SponsorUniversity of North Dakota
ModalityBiologic
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Human Amnion Allograft

What is Human Amnion Allograft?

Human Amnion Allograft is a Biologic drug developed by University of North Dakota.

Who makes Human Amnion Allograft?

Human Amnion Allograft is developed and marketed by University of North Dakota (see full University of North Dakota pipeline at /company/university-of-north-dakota).

Is Human Amnion Allograft also known as anything else?

Human Amnion Allograft is also known as AmnioExCel.

What development phase is Human Amnion Allograft in?

Human Amnion Allograft is FDA-approved (marketed).

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing